New scan may reveal brain tumor drug effects in weeks, not years

NCT ID NCT07469735

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special PET scan (18F-AGX) can detect early changes in brain tumor activity in adults with slow-growing IDH-mutant gliomas who are taking the drug Vorasidenib. Ten participants will get the drug daily for about a year and have multiple PET and MRI scans to see if metabolic changes predict tumor shrinkage or growth. The goal is to find a faster way to tell if the treatment is working, instead of waiting months or years for standard MRI results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse astrocytoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital

    Shanghai, Shanghai Municipality, 201100, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••